← L-Carnitine

Heart Health, Fat Metabolism, and Fertility

How this amino acid derivative shuttles fatty acids into mitochondria to power the heart, support metabolic health, and improve sperm motility

L-carnitine is a naturally occurring compound your body makes from two amino acids — lysine and methionine — primarily in the liver and kidneys. Its central job is moving long-chain fatty acids across the inner mitochondrial membrane so they can be burned for energy. The heart, which runs almost entirely on fat, depends heavily on adequate carnitine supply. Research has linked L-carnitine supplementation to lower cardiac mortality after heart attack [1], improved heart function in heart failure [2], better blood sugar control [3], and improved sperm motility in men with fertility challenges [4].

How L-Carnitine Works

Every cell that burns fat needs carnitine. Long-chain fatty acids — the kind found in meat, fish, and most dietary fat — cannot cross the inner mitochondrial membrane on their own. Carnitine acts as the shuttle: it binds to a fatty acid, ferries it across the membrane, and releases it into the mitochondrial matrix where it enters beta-oxidation and generates ATP.

The heart extracts roughly 60–70% of its energy from fatty acid oxidation, which explains why cardiac tissue contains some of the highest carnitine concentrations in the body. When carnitine is depleted — as happens with kidney disease, long-term valproate or statin use, or very low-meat diets — fatty acids accumulate in the cytoplasm, mitochondrial function deteriorates, and heart muscle weakens.

Dietary sources and biosynthesis

Red meat, particularly beef and lamb, is the richest dietary source — a 3-ounce beef steak delivers roughly 60–80 mg of L-carnitine. Poultry and dairy contribute smaller amounts, while fish (including salmon) provides about one-twelfth as much as beef. Plant foods are essentially carnitine-free. The body synthesizes carnitine endogenously from lysine and methionine, with ascorbic acid, iron, niacin, and pyridoxine all required as cofactors; deficiency in any of these can impair synthesis.

Dosage and forms

The standard supplemental dose studied in most trials is 1–3 g per day of L-carnitine or L-carnitine L-tartrate (a more stable ester form). Glycine propionyl-L-carnitine (GPLC) is used more for athletic performance. Acetyl-L-carnitine, which crosses the blood-brain barrier more readily, is the preferred form for cognitive and neuroprotective applications. See our Acetyl-L-Carnitine page for that specific application.

The TMAO question

L-carnitine is metabolized by gut bacteria into trimethylamine (TMA), which the liver converts to trimethylamine-N-oxide (TMAO). A landmark 2013 Nature Medicine study found that omnivores produced more TMAO from carnitine ingestion than vegans or vegetarians, and that higher TMAO levels were associated with elevated cardiovascular risk in a large observational cohort [5]. This generated significant concern about supplemental carnitine. However, the relationship is more nuanced than it first appeared: fish — one of the most cardiprotective foods studied — is also a potent TMAO source, and dietary carnitine from whole foods has not been associated with increased TMAO to the same degree as high-dose supplementation. The clinical trials showing cardiovascular benefit predate and largely persist despite this concern.

Evidence Review

Cardiovascular disease and post-heart attack recovery

The most cited evidence for L-carnitine and heart health comes from a 2013 meta-analysis by DiNicolantonio and colleagues in Mayo Clinic Proceedings [1]. Their systematic review pooled 13 controlled trials comprising 3,629 participants and compared L-carnitine supplementation against placebo or control in the setting of acute myocardial infarction. L-carnitine was associated with a 27% reduction in all-cause mortality (OR 0.40, 95% CI 0.17–0.93), a 65% reduction in ventricular arrhythmias (OR 0.35, 95% CI 0.21–0.58), and a 40% reduction in angina development. No significant effect was found on heart failure incidence or reinfarction. The authors called for large modern RCTs given the low cost and favorable safety profile of the supplement.

Heart failure

Song et al. conducted a meta-analysis of 17 RCTs enrolling 1,625 chronic heart failure patients [2]. L-carnitine treatment was associated with a significant improvement in left ventricular ejection fraction (LVEF) (weighted mean difference +4.14%, p = 0.01) and stroke volume (WMD +8.21 ml, p = 0.01). Overall clinical efficacy was markedly higher in the treatment group (OR 3.47, p < 0.01). Serum levels of BNP and NT-proBNP — biomarkers of cardiac stress — also fell significantly. Importantly, the intervention was well tolerated with no serious adverse events attributed to L-carnitine.

Blood sugar and insulin resistance

A 2023 dose-response meta-analysis in Frontiers in Nutrition compiled 41 RCTs with 2,900 participants [3]. L-carnitine supplementation produced significant reductions in fasting blood glucose (WMD −3.22 mg/dl), HbA1c (WMD −0.27%), and HOMA-IR (WMD −0.73). Greater effects were observed at doses of 2 g/day or more, with trial durations of at least 12 weeks, and in participants with type 2 diabetes or obesity. The mechanistic explanation involves carnitine clearing excess acyl-CoA derivatives from mitochondria, thereby reducing lipotoxic interference with insulin signaling and improving glucose disposal.

Male fertility

Khaw and colleagues published a systematic review and meta-analysis in Reproduction and Fertility covering RCTs from 2000 to 2020 [4]. Carnitine supplementation (L-carnitine alone or in combination with acetyl-L-carnitine) significantly improved total sperm motility, progressive motility, and sperm morphology in men with idiopathic oligoasthenozoospermia. Effects on sperm concentration were not significant. Pregnancy rates, while numerically improved, did not reach statistical significance — a finding the authors attributed to the small number of studies powered for this outcome. The biological rationale is well established: sperm cells require high ATP output, and carnitine supports mitochondrial energy production in the sperm midpiece where mitochondria are densely packed.

TMAO and cardiovascular risk

The 2013 Koeth et al. study [5] remains the primary evidence for concern. In a mouse model, chronic L-carnitine supplementation promoted atherosclerosis in a microbiota-dependent fashion — germ-free mice did not develop the same plaque burden. Among 2,595 patients undergoing cardiac evaluation, plasma L-carnitine predicted increased major adverse cardiac events only in subjects who simultaneously had elevated TMAO levels, suggesting the relationship is conditional on gut microbiome composition. This underscores the importance of the broader dietary pattern: a gut microbiome shaped by diverse plant foods and fermented foods generates less TMA from carnitine than one shaped by a low-fiber Western diet.

Overall assessment

The evidence for L-carnitine supplementation in cardiovascular protection post-infarction and in heart failure is reasonably strong, drawing on multiple RCTs and consistent meta-analytic findings. The glycemic benefits are moderate but reproducible across a large trial pool. Fertility benefits are real for sperm motility but not yet confirmed for pregnancy rates. The TMAO concern is genuine but appears context-dependent rather than absolute. The supplement has a strong safety record at typical doses of 1–3 g/day, with nausea and GI discomfort the most reported side effects at higher doses.

References

  1. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysisDiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. Mayo Clinic Proceedings, 2013. PubMed 23597877 →
  2. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled TrialsSong X, Qu H, Yang Z, Rong J, Cai W, Zhou H. BioMed Research International, 2017. PubMed 28497060 →
  3. The effects of L-carnitine supplementation on glycemic markers in adults: A systematic review and dose-response meta-analysisZamani M, Pahlavani N, Nikbaf-Shandiz M, Rasaei N, Ghaffarian-Ensaf R, Asbaghi O, Shiraseb F, Rastgoo S. Frontiers in Nutrition, 2023. PubMed 36704801 →
  4. l-carnitine and l-acetylcarnitine supplementation for idiopathic male infertilityKhaw SC, Wong ZZ, Anderson R, Martins da Silva S. Reproduction and Fertility, 2022. PubMed 35128424 →
  5. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosisKoeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Nature Medicine, 2013. PubMed 23563705 →

Transparency

View edit history

Every change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.

Weekly Research Digest

Get new topics and updated research delivered to your inbox.